Skip to content
CharitiesAidWelfare, Medical Health Aged Care

$1.3 Million Partnership Between SunSense And Melanoma Institute Australia Fuels Breakthroughs In Vital Research

Ego Pharmaceuticals 2 mins read
SunSense supports MIA's goal to achieve zero deaths from melanoma.

SunSense and Melanoma Institute Australia (MIA), a global leader in melanoma research and treatment, are celebrating seven years in a partnership which has seen the Australian sunscreen brand donate more than $1.3 million towards MIA's ground-breaking research efforts. 

"MIA's mission to achieve zero deaths from melanoma by 2030 aligns perfectly with SunSense's commitment to help protect and care for the skin of all Australians," says Alan Oppenheim, Managing Director of Ego Pharmaceuticals, the makers of SunSense. "Our partnership not only supports essential research and advanced treatments but also enables us to raise awareness about sun safety and responsible sun protection habits."

MIA is at the forefront of global melanoma research and treatment, driving remarkable advancements that have led to a 50% survival rate for advanced melanoma patients. 
The partnership with SunSense enables vital funding for MIA's Personalised Immunotherapy Platform, a revolutionary approach to treating melanoma that's paving the way for better outcomes for patients.

“Long-term support from Ego Sunsense has been critical in helping fuel our ongoing research to find new and more effective treatments to save lives from melanoma,” said Melanoma Institute Australia CEO Matthew Browne. “However prevention is always better than a cure, and importantly, this partnership also amplifies our key prevention message of using sunscreen which is one of the five sun safe rules.”

As well as providing much needed financial support towards MIA’s research, the partnership is also helping to raise awareness about the dangers of UV exposure and the importance of sun safety. Melanoma, often referred to as 'Australia's national cancer,' is the most common cancer affecting 15 to 39-year-old Australians, making this education imperative.

With over 30 years of expertise, all SunSense products are made in Australia and provide broad-spectrum protection that is suitable for all skin types. As well as being fragrance-free and dermatologically tested, SunSense sunscreens are enriched with Vitamin B3 (Nicotinamide) to moisturise and visibly improve skin texture. 

This season SunSense is proudly adding two new products to its range, providing even more options for individuals and families to choose the protection that suits them best. 

SunSense Sensitive Protect SPF50 is specifically formulated for sensitive skin and children 6 months and up, and also has 4 hours water resistance, so it’s fantastic for those Summer beach days! 

SunSense Face Ultra Light SPF50+ is a lightweight facial sunscreen that’s enriched with moisturising Vitamin B3 and antioxidants, and is non-comedogenic so it won’t clog your pores. 

Available in pharmacies nationwide, SunSense remains steadfast in its dedication to helping Australians enjoy the outdoors while prioritising their skin's health.

Always read the label and follow the directions for use. Avoid prolonged sun exposure and wear protective clothing, hats and eyewear to further reduce risk. Frequent re-application is required.

Contact details:

Kim Scata
Communications & Partnerships Executive
Phone: +61 403 661 936


More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.